At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 152 enrolled
Drug / intervention
Tirzepatidedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-Label, Single-Arm, Phase 4 Study to Assess Glycemic Control When Adults With Type 2 Diabetes Switch From a GLP-1 RA to Tirzepatide (SURPASS-SWITCH-2)
In Brief
A Phase 4 clinical trial evaluating Tirzepatide for Type 2 Diabetes and Diabetes Mellitus, Type 2. Completed, enrolled 152 participants across 32 sites.
Detailed Summary
The main purpose of this study is to investigate the effects of switching from glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy to tirzepatide glucose-dependent insulinotropic polypeptide (GIP) GLP-1 RA agonist in participants with type 2 diabetes (T2D).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes, Diabetes Mellitus, Type 2
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
2023202420252026
First PostedJan 2023
Enrollment StartMar 2023
Primary CompletionOct 2023
TodayJul 2026
First PostedJan 31, 2023
Enrollment StartMar 8, 2023
Primary CompletionOct 31, 2023
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 3.4 years ago
Interventions
Tirzepatidedrug
Administered SC